Clinical trial
Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer
NCT02124317 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer
- Lead sponsor
- Chinese PLA General Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 30, 2014
- Completion date
- May 31, 2017
- Enrollment
- 60 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced pancreatic cancer